- Home
- PINE vs VNDA Comparison
PINE vs VNDA Comparison
Compare PINE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- VNDA
- Stock Information
- Founded
- PINE 2019
- VNDA 2002
- Country
- PINE United States
- VNDA United States
- Employees
- PINE N/A
- VNDA N/A
- Industry
- PINE Real Estate Investment Trusts
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- VNDA Health Care
- Exchange
- PINE Nasdaq
- VNDA Nasdaq
- Market Cap
- PINE 219.7M
- VNDA 237.9M
- IPO Year
- PINE 2019
- VNDA 2006
- Fundamental
- Price
- PINE $15.32
- VNDA $4.34
- Analyst Decision
- PINE Strong Buy
- VNDA Strong Buy
- Analyst Count
- PINE 8
- VNDA 3
- Target Price
- PINE $19.00
- VNDA $15.33
- AVG Volume (30 Days)
- PINE 63.8K
- VNDA 519.0K
- Earning Date
- PINE 07-17-2025
- VNDA 05-07-2025
- Dividend Yield
- PINE 7.44%
- VNDA N/A
- EPS Growth
- PINE N/A
- VNDA N/A
- EPS
- PINE 0.07
- VNDA N/A
- Revenue
- PINE $53,967,000.00
- VNDA $201,351,000.00
- Revenue This Year
- PINE $7.94
- VNDA $16.86
- Revenue Next Year
- PINE $2.82
- VNDA $39.78
- P/E Ratio
- PINE $206.04
- VNDA N/A
- Revenue Growth
- PINE 14.94
- VNDA 13.37
- 52 Week Low
- PINE $14.51
- VNDA $3.81
- 52 Week High
- PINE $19.42
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- PINE 49.88
- VNDA 51.79
- Support Level
- PINE $14.66
- VNDA $4.17
- Resistance Level
- PINE $15.30
- VNDA $4.41
- Average True Range (ATR)
- PINE 0.26
- VNDA 0.16
- MACD
- PINE 0.07
- VNDA 0.03
- Stochastic Oscillator
- PINE 83.75
- VNDA 73.61
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.